John Mendelsohn: A visionary scientist, oncologist and leader

Dr. John Mendelsohn is credited for the concept of targeting the epidermal growth factor receptor (EGFR), providing the first evidence of anticancer activity of antagonist anti-EGFR mAb, and developing the Erbitux (Cetuximab) drug for cancer patients. During his professional journey, Dr. Mendelsohn...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rakesh, Murad, Ferid, Bogler, Oliver, O'Malley, Bert W., Hortobagyi, Gabriel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872667/
https://www.ncbi.nlm.nih.gov/pubmed/31798764
http://dx.doi.org/10.18632/genesandcancer.195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872667/
https://www.ncbi.nlm.nih.gov/pubmed/31798764
http://dx.doi.org/10.18632/genesandcancer.195

Ejemplares similares